Core Insights - Bio-Techne reported second-quarter fiscal 2026 results that were largely in line with internal expectations, with organic revenue flat due to strength from large pharmaceutical customers offset by softness in emerging biotech and U.S. academia [4][6] - Adjusted EPS was $0.46, reflecting a 10% year-over-year increase, while GAAP EPS was $0.24, up from $0.22 a year earlier [1][4] - The company expects Q3 organic growth to mirror Q2, with specific headwinds from cell therapy timing and an OEM order shift [4][22] Financial Performance - Total revenue for the quarter was $295.9 million, flat year over year on both a reported and organic basis, with foreign exchange providing a 2% tailwind [6] - Adjusted operating margin expanded approximately 100 basis points to 31.1%, despite a decline in adjusted gross margin to 68.5% due to unfavorable product and customer mix [5][7] - Profitability improved, with adjusted EPS increasing to $0.46 and operating margin expansion expected to continue for the full fiscal year [5][16] Segment Performance - Protein Sciences reported sales of $215.1 million, up 2% year over year, but organic revenue declined 1% [8] - Diagnostics and Spatial Biology posted Q2 sales of $81.2 million, down 4% year over year, with organic growth of 3% after accounting for the Exosome Diagnostics divestiture [10][11] - The cell therapy business experienced a decline of over 30%, including a 50% drop in GMP reagents, due to a purchasing pause related to FDA Fast Track designations [9] Geographic Trends - China and broader APAC regions showed strong growth, with China growing mid-single digits and APAC approaching 20% [12] - The Americas experienced a decline in high single digits, though adjusting for cell therapy order timing, the region grew low single digits [13] - EMEA was flat compared to a strong prior year, with diagnostics strength offset by order timing dynamics [13] Market Dynamics - Large pharma revenue increased low double digits for the fourth consecutive quarter, while emerging biotech declined mid-single digits, indicating a split in market performance [14] - U.S. academic revenue reported a low single-digit decline overall, with some stability noted in Europe [14] - Management highlighted constructive developments in U.S. federal funding proposals, including a budget increase and maintained indirect funding rates [14] Future Outlook - The company anticipates Q3 organic growth to be consistent with Q2, with underlying trends expected to improve [15][16] - Management expects mid-single-digit underlying growth for the remainder of the business, with sequential improvement anticipated as revenue increases seasonally [16] - Strategic themes discussed included investments in cell therapy, proteomic analysis instruments, and spatial biology, positioning the company for gradual end-market improvement [19][18]

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to release its second-quarter fiscal 2026 results on February 4, with adjusted earnings per share (EPS) anticipated at 43 cents, reflecting a 2.4% increase from the previous year, while revenues are projected at $292 million, indicating a 1.7% decrease year-over-year [1][2]. Group 1: Earnings Performance - In the last reported quarter, Bio-Techne posted adjusted EPS of 42 cents, matching the Zacks Consensus Estimate, with the company beating earnings in three of the last four quarters and matching once, averaging a surprise of 6.58% [1]. - Estimates for earnings have remained constant at 43 cents over the past 30 days, indicating stability in expectations leading up to the announcement [3]. Group 2: Revenue Estimates - The Zacks Consensus Estimate for revenues is set at $292 million, which represents a decrease of 1.7% from the year-ago figure [2]. - The consensus estimate for the Spatial Biology segment's revenues is pegged at $81.6 million, down 3% from the previous year [15]. Group 3: Factors Influencing Performance - Ongoing macro uncertainties, including tariffs and potential NIH budget cuts, may add to customer uncertainty and temporarily slow growth momentum in the second quarter of fiscal 2026 [4]. - The timing related to cell therapy programs negatively impacted sales in the previous quarter, and this trend is expected to continue [5]. - The core portfolio of research-use-only proteomic agents, featuring over 6,000 proteins and 400,000 antibody types, is likely to support global customers in advancing therapeutics for precision diagnostics [6]. Group 4: Segment Developments - The protein analytical instrumentation business is expected to maintain strong momentum, with the ProteinSimple solution resuming double-digit growth [7]. - Demand for the next-generation high-throughput instrument, Leo, appears to be strong, contributing positively to quarterly results [8]. - Major developments include a licensing agreement with Monod Bio for exclusive rights to a subset of AI-designed bispecific binding proteins and a strategic distribution partnership with Sphere Bio for ultrasensitive immunoassays targeting Alzheimer's biomarkers [10]. Group 5: Challenges and Growth Areas - The Spatial Biology segment may face revenue declines due to the divestiture of the Exosome Diagnostics business, despite growth in the RNAscope product suite [12]. - The segment is likely to encounter headwinds from NIH funding uncertainties and a weaker biotech funding environment [13]. - The company has launched several new products and partnerships aimed at enhancing its offerings in spatial biology and diagnostics, which may contribute to top-line performance [14].

Bio-Techne FY Conference Summary Company Overview - **Company Name**: Bio-Techne (NasdaqGS: TECH) - **Headquarters**: Minneapolis - **Employee Count**: 3,100 across 34 global locations - **Revenue**: $1.2 billion in 2025 - **Segments**: - Protein Sciences (73% of revenue) - Diagnostics and Spatial Biology (27% of revenue) [3][4] Core Business Insights - **Product Portfolio**: - 6,000 proteins and 400,000 antibodies - Focus on consumables (81% of revenue), instruments (9%), services (7%), and royalties (2%) [4] - **Revenue Breakdown**: - 41% from core reagents - 12% from diagnostic controls - 51% from biopharma, 20% from academia, 16% from diagnostics, 13% from distributors [5][6] Market Position and Strategy - **Total Addressable Market (TAM)**: $27 billion with significant growth potential [18][22] - **Growth Factors**: - Discovery of biological insights - Development of advanced therapeutics - Enablement of precision diagnostics [9][10] - **Key Applications**: - Cell therapies (7% of revenue) - Proteomic applications in drug development - Spatial interrogation [10][13] Financial Performance - **Revenue Growth**: 10% CAGR over the last five years despite market headwinds [19] - **Organic Revenue Growth**: 5% in fiscal 2025 [20] - **Profitability**: Targeting 35%-40% operating margins [23] Industry Trends - **Biotech Industry**: Experienced a decline in Q1 but showed signs of recovery with a 90% increase in funding in Q4 [24][25] - **Academic Sector**: Stabilizing with a shift in research focus from infectious diseases to chronic diseases [25][26] - **China Market**: Contributing 8% of revenue, showing potential for growth due to favorable government policies and funding [28][29] Cell Therapy Insights - **Growth in Cell Therapy**: Revenue reached $80 million, with $60 million from GMP proteins [30] - **Fast-Track Designation**: Two major customers received fast-track designation, potentially leading to significant future revenue [30][31] - **Clinical Trials**: 57% increase in cell therapy trials year-over-year [32] Diagnostics and Spatial Biology - **Market Size**: $5 billion for spatial biology, with 75% in translational and clinical markets [35] - **Innovations**: Introduction of RNAscope for RNA detection and COMET for multi-omic analysis [36][37] Future Outlook - **Growth Projections**: Anticipating low single-digit growth for fiscal 2026 due to current market conditions [41] - **Innovation Focus**: Continued investment in R&D (8% of revenues) and new product launches, including AI-designed proteins and ultra-sensitive immunoassays [38][39] - **M&A Strategy**: Plans to pursue acquisitions to enhance cell therapy and proteomic analytical capabilities [42] Conclusion - Bio-Techne is positioned for sustained growth through its differentiated product portfolio, strategic market focus, and commitment to innovation, despite facing short-term challenges in the biotech and academic sectors. The company aims to leverage its strengths to navigate market fluctuations and capitalize on emerging opportunities.

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Sciences Tools - **Established**: 50 years ago - **Core Products**: 7,000 proteins and 400,000 antibodies, serving as foundational components for life science research tools [2][4] Key Business Areas 1. **Cell Therapy**: Focus on growing immune and regenerative cells to treat diseases [2][3] 2. **Proteomics**: Emphasis on proteomic analysis, with a belief in market growth potential [3][4] 3. **Spatial Biology**: Investigating tissue interactions to assess therapy effectiveness [3][4] 4. **Molecular Diagnostics**: Capable of analyzing difficult-to-read genes, addressing gaps in next-generation sequencing (NGS) [3][4] Recent Financial Performance - **Q1 2026 Results**: - Cell therapy business showed rapid growth, with 60% and 90% growth in previous quarters [5] - Two major customers received FDA Fast Track approval, leading to expected revenue boosts [5][22] - Large pharma customers continued double-digit growth for three consecutive quarters [6] - China market showed positive growth for two consecutive quarters [6] - Margins improved to 29.9%, exceeding the forecast of 20% [6] Market Insights - **Biopharma Market**: - Accounts for 50% of revenue; large pharma contributes 30% of that [8] - Large pharma showed resilience despite tariff concerns, while biotech funding declined mid-teens year-over-year [8][9] - Recent M&A activity and lower interest rates are expected to stabilize biotech funding [9] - **Academic Research Market**: - Represents 20% of revenue; U.S. academic research is 12% and Europe is 8% [10] - U.S. market faced turbulence due to budget cuts and funding shifts, but bipartisan support is anticipated [11] - Shift in funding focus from infectious diseases to neurology, oncology, and weight management [11][12] - **China Market**: - Historically significant growth driver, currently at 8% of revenue [14] - Increased sensitivity towards life sciences post-COVID, with a focus on novel modalities [15] - Expected growth in the mid-teens as activity levels improve [16] Product Innovations - **R&D Investment**: Over 8% of revenues reinvested into R&D [17] - **Key Innovations**: - AI-enhanced protein design for improved stability and sensitivity [17] - ProPak for cell therapy, reducing contamination risks [18] - Leo protein analysis instrument for high-volume testing [18] - Multi-omics method for spatial biology [19] - ESR1 breast cancer test for treatment resistance [20] Strategic Acquisitions - **Wilson Wolf**: Bio-Techne plans to acquire the remaining 80% of Wilson Wolf by 2027, enhancing its cell therapy capabilities [24][25] Market Outlook - **Fiscal 2026 Expectations**: - Anticipated single-digit growth, with potential for double-digit growth in normalized market conditions [28][29] - Recovery expected in biotech and academic markets, with stabilization in large pharma [30][31] - Continued market share gains anticipated in protein analytics and spatial biology [32] Conclusion - Bio-Techne is positioned for growth through strategic innovations, market recovery, and a focus on high-demand areas within the life sciences sector. The company is optimistic about future performance as market conditions stabilize and improve.

Financial Data and Key Metrics Changes - The company ended Q1 with a negative growth of 1%, but when excluding two large cell therapy customers, the growth for the rest of the business was approximately 1% [6][8] - The company anticipates a similar overall growth rate for Q2, projecting a negative growth of 1% again, but with an adjusted growth of 3% when excluding the impact of the two customers [25][96] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating strong performance despite market challenges [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in many recent quarters, indicating its resilience in a tough market [26][68] - The Spatial Biology segment saw flat revenue in Q1, but bookings increased double-digit, suggesting a positive trend moving forward [27][74] Market Data and Key Metrics Changes - The pharmaceutical market, which constitutes 30% of the company's revenue, has shown recovery with double-digit growth in recent quarters, alleviating previous concerns about regulatory impacts [11][12] - Academic market performance has improved, with expectations of a flat NIH budget, leading to reduced anxiety among academic customers [13][66] - Biotech funding has improved from a decline of 30% to a decline of 13%, indicating a potential stabilization in the biotech market [16][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial Biology franchises to drive growth, especially as the market stabilizes [26][29] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term challenges due to the two large customers [90][94] - The company is leveraging its strong customer relationships and grant programs to maintain interest in cell therapy, indicating a strategic focus on early-stage development support [92] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [11][13] - The company expects to see improvements in the biotech market, but anticipates that significant revenue contributions from this sector may not materialize until fiscal year 2027 [22][57] - Management highlighted the importance of upcoming FDA approvals and commercialization timelines for the two large customers, which could significantly impact future revenue [49][50] Other Important Information - The company has a diverse customer base, with 700 customers, and is actively seeking to expand its market presence despite current challenges [91] - The company is experiencing a high level of interest in its instruments, indicating potential for future growth as capital expenditures begin to recover [71] Q&A Session Summary Question: What is the impact of the two large customers on the business? - The two large customers accounted for 35%-40% of GMP revenue at their peak, and their absence is expected to impact revenue for the remainder of the fiscal year [41][52] Question: How does the company view the future of the cell therapy market? - Management believes the quality of new clinical trials is improving, and despite current funding challenges, interest in cell therapy remains high [90][92] Question: What are the expectations for the diagnostics business moving forward? - The diagnostics business is expected to continue performing well, with a more even revenue distribution anticipated throughout the year [30][31]

Financial Data and Key Metrics Changes - The company ended Q1 with a -1% growth, primarily impacted by two large cell therapy customers who did not purchase materials, contributing approximately 200 basis points of headwind [6][8] - Adjusted for these customers, the growth rate for the rest of the company was +1% [25] - The company anticipates a similar overall growth rate for Q2, projecting a decline of -1% but an improvement to +3% when excluding the impact of the two customers [25][26] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating a strong performance despite lumpiness in customer purchasing patterns [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in most recent quarters, indicating strong demand for its consumables [26][68] - The Spatial Biology segment experienced a flat performance in Q1 after a down quarter in Q4, but bookings increased double-digit, suggesting a recovery in interest [27][75] Market Data and Key Metrics Changes - The Pharma market, which constitutes 30% of the company's revenue, has shown resilience with double-digit growth returning after a brief slowdown due to regulatory concerns [12][61] - Academic market funding has stabilized, with NIH budget expectations now flat, improving customer sentiment and reducing anxiety [13][66] - Biotech funding has improved from a -30% decline to -13%, indicating a potential recovery in spending [16][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial Biology franchises to drive growth in a stabilizing market, leveraging historical performance to navigate current challenges [26][29] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term headwinds from key customers [89][92] - The strategy includes maintaining strong relationships with existing customers while exploring new opportunities in the biotech space [54][94] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [11][13] - The company expects to see a gradual recovery in the biotech sector, with funding translating into spending over the next few quarters [57] - Management highlighted the importance of upcoming FDA approvals and commercialization timelines for key customers, which could significantly impact future revenue [49][50] Other Important Information - The company has seen a significant increase in its customer base, growing from 550 to 700 customers, indicating strong interest in its products [92] - The company is actively engaging in grant programs to support early-stage cell therapy developments, which could lead to long-term customer loyalty [93] Q&A Session Summary Question: What is the impact of the two large customers on the business? - The two customers accounted for 35%-40% of GMP revenue at their peak, and their absence will significantly impact revenue for the remainder of the year [41][52] Question: What is the expected timeline for commercialization of the therapies from these customers? - Management anticipates a timeline of 18 months to three years for commercialization following phase III results, with a base case of fiscal year 2028 for potential revenue [49][50] Question: How does the company view the current state of the cell therapy market? - Management believes the quality of new clinical trials is improving despite a slowdown in the rate of growth, indicating a healthy future for the sector [92]

Financial Data and Key Metrics Changes - The company ended Q1 with a negative growth of 1%, but excluding two large cell therapy customers, the growth for the rest of the business was approximately 1% [6][8] - The company anticipates a similar overall growth rate for Q2, projecting a decline of about 1% but an improvement to 3% when excluding the impact of the two customers [25][30] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating a strong performance despite fluctuations [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in recent periods, suggesting resilience in a challenging market [26][70] - The Spatial Biology segment experienced a flat performance in Q1 after a down quarter, but bookings increased double-digit, indicating potential for recovery [27][75] Market Data and Key Metrics Changes - The pharmaceutical market, which constitutes 30% of revenue, has shown recovery with double-digit growth in recent quarters, alleviating previous concerns about regulatory pressures [12][13] - Academic market conditions have stabilized, with expectations of a flat NIH budget, improving sentiment among academic customers [14][66] - Biotech funding has improved, with funding levels increasing from a decline of 30% to a decline of 13%, suggesting a potential recovery in spending [17][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial franchises to drive growth, especially as market conditions stabilize [26][75] - The strategy includes leveraging the strong demand for consumables and reagents associated with their instruments, which are expected to enhance margins over time [77][80] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term challenges, due to the high quality of clinical trials being conducted [92][94] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [12][14] - The company anticipates that improvements in funding and market conditions will begin to reflect in financial results by the second half of fiscal year 2026 [22][58] - Management highlighted the importance of maintaining strong relationships with customers and adapting to their needs as market conditions evolve [43][59] Other Important Information - The two large customers in the cell therapy space accounted for as much as 35%-40% of GMP revenue at their peak, but their absence is expected to impact revenue significantly in the near term [41][90] - The company has a diverse customer base, with 698 other customers, and is actively seeking to expand its reach in the cell therapy market through grant programs [94][96] Q&A Session Summary Question: What is the impact of the two large customers on revenue? - The two customers have significantly influenced revenue, making up a large portion of GMP revenue, and their absence is expected to reduce business temporarily [41][90] Question: How does the company view the recovery in the biotech market? - The company sees a lag of 2-3 quarters before funding translates into spending, but is optimistic about a recovery in fiscal year 2027 [58] Question: What are the expectations for the diagnostics business? - The diagnostics business is expected to continue performing well, with a more even revenue stream anticipated throughout the year [30][31] Question: How is the company addressing margin progression? - Management expects margin expansion to be consistent with revenue growth, projecting at least a 100 basis point improvement for the year [97]

New Listing & Cryptocurrency - Bitget Onchain 上线新的加密货币项目，寻找下一个百倍币 [1] - 新上线的加密货币包括 $ZEUS, BONKPUTER, $BSTR, Bubble, $JUGS, $COMET, $AiMau [1] Platform Information - 用户可以通过 Bitget App 的 Markets → Onchain 访问这些新币 [1]

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Company Developments - Bio-Techne Corporation has opened a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer service across the EMEA region and supporting long-term growth [1] - The new centre is set to open in the first half of 2026 and will complement the existing Demonstration Laboratory in the UK, chosen for its strategic location in a thriving life sciences sector [2] - The facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, including the recently launched Leo System and the COMET spatial biology platform [3] Industry Prospects - The life science market is projected to grow at a compound annual growth rate (CAGR) of 10.28% from 2024 to 2033, driven by technological advancements, demand for personalized medicine, and increased R&D investments [4] Other Developments - Bio-Techne's brand Asuragen has partnered with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit, a new genetic panel for carrier screening research [5] - The company has expanded its RNAscope in situ hybridization probes portfolio to over 70,000 unique probes across more than 450 species, enhancing spatial biology research [6] Competitive Landscape - Competitor QIAGEN N.V. has enhanced its QIAcuity dPCR system, doubling the number of targets analyzed from a single sample, and partnered with Genomics England for the 100,000 Genomes Project [8] - Thermo Fisher Scientific's Olink Explore Platform has been selected for the UK Biobank Pharma Proteomics Project, aiming to analyze over 5,400 proteins from 600,000 samples [9] - Bio-Rad has made advancements in its ddPCR platform and invested in Geneoscopy for a non-invasive colorectal cancer screening test [11]